---
title: Symcel enters into R&D collaboration with Johnson & Johnson to advance rapid sterility testing in cell & gene therapies
description: Symcel enters into strategic R&D collaboration with Johnson & Johnson to advance rapid sterility testing in cell & gene therapies.
---

[[New] News / events ](https://symcel.com/news-events)

# [Symcel enters into R&D collaboration with Johnson & Johnson to advance rapid sterility testing in cell & gene therapies](https://symcel.com/news-events/symcel-enters-into-rd-collaboration-with-johnson-johnson-to-advance-rapid-sterility-testing-in-cell-gene-therapies)

 Written by [Per Lidén](https://symcel.com/news-events/author/per-lidén) | Sep 16, 2025 11:22:03 AM

We’re proud to announce a strategic research collaboration with Johnson & Johnson* to accelerate and validate Symcel’s next-generation platform for rapid sterility testing.

Through this collaboration, we aim to push forward technology development, data generation and regulatory approvals to implement the new Symcel platform.

Symcel is a leader in microbial detection methods powered by biocalorimetry. Our platform is designed to drastically shorten sterility release timelines—long a bottleneck in advanced therapy manufacturing—by providing faster, more reliable results that integrate into manufacturing workflows.

Sterility testing is the most time-consuming step in releasing cell therapies. Current methods can take 7–14 days, delaying access to critical treatments. This collaboration aims to deliver a validated, GMP-compliant test that cuts release time to under 3 days—improving manufacturing efficiency with faster access for patients.

Symcel CEO Dr. Jesper Ericsson comments: *“We are very pleased to enter into this collaboration and look forward to seeing the potential of Symcel’s platform reduce the vein-to-vein time within cell & gene therapy manufacturing.”*

Learn more about [Symcel rapid sterility testing solutions for cell and gene therapies.](https://symcel.com/applications/rapid-sterility-testing/)

 

* Legal entity, Janssen Pharmaceutica NV

Media contact:  
Per Lidén, Marketing Manager  
per.liden@symcel.com

 

 

 

[View full post](https://symcel.com/news-events/symcel-enters-into-rd-collaboration-with-johnson-johnson-to-advance-rapid-sterility-testing-in-cell-gene-therapies)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Per Lidén"
  },
  "dateModified" : "2025-09-16T11:26:19.982Z",
  "datePublished" : "2025-09-16T11:22:03Z",
  "headline" : "Symcel enters into R&D collaboration with Johnson & Johnson to advance rapid sterility testing in cell & gene therapies",
  "image" : {
    "@type" : "ImageObject",
    "height" : 628,
    "url" : "https://25649679.fs1.hubspotusercontent-eu1.net/hubfs/25649679/Announcement%20%2860%29.jpg",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://symcel.com/news-events/symcel-enters-into-rd-collaboration-with-johnson-johnson-to-advance-rapid-sterility-testing-in-cell-gene-therapies",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "[New] News / events"
  }
}
```